 |
|
||||||||||||||||
 |
|||||||||||||||||
 |
||
 |
Availability
Diclofenac oral doses of 1.0-1.2 g·h−1 (15-22 times the recommended oral dose) for 6 months, and patients who continued to be able walk at least to a point between 4 and 6 feet (1.5-2.0 m), in accordance with the manufacturer's labeling (25,26). In a previous study, we found that patients were no more likely to experience adverse events when their initial dosage was doubled (27), and this may be the reason study used such highly potent diclofenac. The major top 10 drugstore mascaras uk adverse effect of oral diclofenac is the development of osteonecrosis and osteosclerosis during treatment because of the destruction bone marrow and marrow-derived cells their subsequent inability to maintain blood platelet numbers or produce anticoagulant hormones (28,29). Some reports have described the development of osteonecrosis after multiple doses oral diclofenac (30,31), but most reports described symptoms arising after 5-10 doses (32,33). The initial rate and intensity of symptoms were significantly higher in patients with coagulation abnormalities (18,34-39), and later reports characterized the development of bone marrow suppression, mineral density abnormalities, and blood clotting abnormalities in response to repeated oral doses (40-48). The extent of symptoms was increased in patients with a history of bone marrow suppression (35); furthermore, the treatment response was not consistent among patients with complete marrow suppression. These findings suggest that the development of bone marrow suppression alone or in combination with other adverse effects may be particularly important in the early phases of therapy and may play key roles in the development of aplastic anemia. Celitinib therapy was associated with an increased incidence and duration of bone marrow suppression and serum creatinine elevation, as compared with placebo (49); however, the extent to which di | |